Mike Liu
Executive Vice President
Healthcare
alphamab
China
Biography
Dr. Liu obtained his Ph.D. at Eppley Cancer Research Institute in the US. In his earlier career, he conducted translational medical research at Yale School of Medicine. Prior to joining Alphamab in 2016, Dr. Liu held increasing responsibilities in global business development at Purdue Pharma, Alexion and Hengrui. He closed multiple deals in licensing, R&D alliance, product acquisition and commercialization partnership, such as the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from Tesaro.
Research Interest
Dr. Liu obtained his Ph.D. at Eppley Cancer Research Institute in the US. In his earlier career, he conducted translational medical research at Yale School of Medicine. Prior to joining Alphamab in 2016, Dr. Liu held increasing responsibilities in global business development at Purdue Pharma, Alexion and Hengrui. He closed multiple deals in licensing, R&D alliance, product acquisition and commercialization partnership, such as the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from Tesaro.
